FDA Approves Biogen’s Drug for Rare Form of ALS
The drug, which will be sold as Qalsody by the [...]
FDA Approves, Leqembi, New Treatment for Early Alzheimer’s
The drug, Leqembi, may modestly slow cognitive decline in early [...]
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The report said the F.D.A.’s approval process for Aduhelm was [...]
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The drug, lecanemab, made by Eisai and Biogen, also carried [...]
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage [...]
Biogen Agrees to Pay $900 Million to Settle Lawsuit Over Kickbacks
The company was accused of illegally paying doctors to prescribe [...]
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, [...]
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious [...]
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
The Alzheimer’s Association has pushed relentlessly to get broad access [...]
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision
Medicare officials are trying to determine whether to cover Aduhelm, [...]